Jänne, Pasi APasi AJännePlanchard, DavidDavidPlanchardKobayashi, KunihikoKunihikoKobayashiCheng, YingYingChengLee, Chee KhoonChee KhoonLeeValdiviezo, NataliaNataliaValdiviezoLaktionov, KonstantinKonstantinLaktionovYang, Tsung-YingTsung-YingYangYu, YanYanYuKato, TerufumiTerufumiKatoJiang, LiyanLiyanJiangChewaskulyong, BusyamasBusyamasChewaskulyongLucien Geater, SarayutSarayutLucien GeaterMaurel, Jean-MarcJean-MarcMaurelRojas, CarlosCarlosRojasTakahashi, ToshiakiToshiakiTakahashiHavel, LiborLiborHavelShepherd, Frances AFrances AShepherdTanaka, KentaroKentaroTanakaGhiorghiu, DanaDanaGhiorghiuAmin, Neha PNeha PAminArmenteros-Monterroso, ElenaElenaArmenteros-MonterrosoHuang, XiangningXiangningHuangChaudhry, Ammar AhmedAmmar AhmedChaudhryCHIH-HSIN YANG2024-03-282024-03-282024-03-010732183Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/641513We report CNS efficacy of first-line osimertinib plus chemotherapy versus osimertinib monotherapy in patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) from the phase III FLAURA2 study according to baseline CNS metastasis status.enjournal article10.1200/JCO.23.02219380425252-s2.0-85184392309https://api.elsevier.com/content/abstract/scopus_id/85184392309